Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA) announced that they have reached a settlement and license agreement with Regeneron (REGN) concerning the launch of AVT06, Alvotech’s proposed biosimilar to Eylea in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech Completes $108 Million Convertible Bond Offering to Drive R&D and Biosimilar Launches
- Alvotech initiated with an Underweight at Barclays
- Alvotech price target lowered to $10 from $14 at Morgan Stanley
- Alvotech’s AVT03 Biosimilar Gains European Approval
- Alvotech announces European Commission approval for AVT03